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Controlling the activity of sirtuins is of high biomedical relevance as the enzymes are involved in cancer,
neurodegeneration and other diseases. Therefore structural elements of 3,4-bisindoylmaleimides (BIMs),
which are known NAD+-dependent histone deacetylase (sirtuin) inhibitors, were merged with
photochromic diarylmaleimides to yield photoswitchable enzyme inhibitors. The new inhibitors show
excellent photophysical properties, are switchable even in polar solvents, and subtype selective against
hSirt2. The inhibitory activity changes up to a factor of 22 for the two photoisomers and physiological
properties can therefore be eﬀectively toggled by irradiation with light of diﬀerent wavelengths. Docking
experiments using the enzyme crystal structure explain the observed activity changes based on the steric
demand of the thiophene substitution and the rigidity of the molecular structure.Introduction
Photochromism has recently received increasing attention due
to a variety of potential applications in molecular optoelec-
tronics, optical data storage and as molecular switches.1–3 The
interest in photopharmacology is revealed by the increasing
number of reported photochromic enzyme inhibitors,4–6 ion
channel blockers7 and receptor ligands8,9 demonstrating the
importance of such compounds as tools for the investigation of
cellular processes and pathogeneses in life sciences.10 Two
strategies are applied for controlling enzyme activity by light:
the photochromic moiety can either be attached to the scaﬀold
of a known substrate or is the linker between two ligands. The
latter approach allows the light-induced change of the ligand
spacing, which is useful for targets with two binding sites.2
Various types of photochromic compounds have been devel-
oped so far, for instance spiropyranes, azobenzenes, fulgides
and diarylethenes (DTEs).2 Diarylmaleimide derivatives are well
known for their photochromic properties and their ability to
change conformational mobility reversibly upon irradiation
(Fig. 1). Both photoisomers are thermally stable and showity of Regensburg, 93040 Regensburg,
.uni-regensburg.de
sity of Freiburg, 79104 Freiburg, Germany
y, Martin Luther University of Halle
iology, University of Gothenburg, 41296
(ESI) available: Detailed experimental
and 11, additional spectral data,
data and docking studies of 2, 3 andtypically a high switching fatigue resistance. In comparison to
other DTEs, the absorption of diarylmaleimides is shied
bathochromically and therefore the isomerization is possible at
longer wavelengths, which reduces cell damage, otherwise
caused by high energy light. The optical properties and the
slightly better water solubility makes them interesting candi-
dates for photochromic inhibitors.1 However, to be useful in
biological applications, photochromic compounds should also
undergo photochromic reactions in polar solvents. One hand-
icap of diarylmaleimides is that these reactions are disfavoured
in polar solvents due to a twisted intramolecular electron charge
transfer (TICT) from the donor aryl part to the electron acceptor
maleimide moiety.11–13
There is an ongoing interest in the regulation of enzyme
activity in the eld of epigenetics, particularly with regard to
anticancer research. NAD+-dependent histone deacetylases also
termed sirtuins are enzymes, which deacetylate histones and
certain non-histone proteins. Sirtuins (Sirt1–7) represent the
class III of four histone deacetylases (HDACs). Their activity isFig. 1 Sirtuin inhibitor 1 (Ro31-8220) and by way of example the
structural related photochromic diarylmaleimide 2, which interconvert
reversible by irradiation with light of diﬀerent wavelength between the
open and closed photoisomer.
This journal is © The Royal Society of Chemistry 2014
Scheme 1 Synthetic strategy with reagents and conditions for 11: (a)
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View Article Onlinedependent on nicotinamide adenine dinucleotide (NAD+),
whereas the other classes are zinc-dependent amidohy-
drolases.14–16 The biological activity of sirtuins has been linked
to the pathogenesis of cancer17 as well as viral,18 metabolic19,20
and neurological diseases.21,22 As several disorders are linked to
the perturbation of HDACs, they are a promising target for drug
discovery. Various class I and II HDACs anticancer drugs are
already in clinical trials or approved as therapeutics.23 To get
more insight into the biological activity and molecular mecha-
nism of all class III HDAC members there is a need to investi-
gate potent and isotype selective small molecule modulators for
human sirtuins. Several lead structures for small-molecule sir-
tuin inhibitors have been identied so far.16 Besides nicotin-
amide as the endogenous inhibitor, splitomicins, suramins,
indoles as well as kinase inhibitors like bisindoylmaleimides
(BIMs) are of particular interest.14–16 Diarylmaleimides are
stable photochromic compounds and structurally related to
BIMs like 1 (Ro31-8220), a potent sirtuin inhibitor (Fig. 1).14 We
envisioned that merging the structure of the DTE chromophore
and the BIM pharmacophore to new diarylmaleimides would
lead to photochromic sirtuin inhibitors. Variation of the
substitution pattern and molecular docking experiments
provides insight into the binding mode of the diarylmaleimides
and their photoisomers to the active site of the enzyme and
thereby lead to potent and isotype selective inhibitors for
sirtuins.acetyl chloride, AlCl3, CH2Cl2, 0 C, 2 h, (84%); (b) TTN, HClO4, MeOH,
RT, overnight, (83%); (c) Pd2(dba)3, XPhos, phenylboronic acid, K3PO4,
1,4-dioxane, 100 C, overnight, (52%); (d) methyl chlorooxoacetate,
AlCl3, CH2Cl2, 0 C, 2 h, (73%); (e) Pd2(dba)3, XPhos, phenylboronic
acid, K3PO4, 1,4-dioxane, 100 C, overnight, (63%); (f) aq. NH3, THF, RT,
overnight, (80%); and (g) KOtBu (1 M in THF), THF, 0 C/ RT, over-
night, (17%).Results and discussion
Synthesis
A common strategy for the synthesis of 3,4-diarylmaleimides is
the intramolecular Perkin-type condensation.24,25 The synthesis
of compound 2 (Fig. 2) was previously described by Scandola
et al.3 Adapted from this synthesis, the non-symmetric mal-
eimide 3 was prepared in a similar manner with further func-
tionalization by Suzuki coupling (see ESI†).
Unfortunately, compound 11 could not be obtained by this
strategy. Hence, we developed an alternative route for the
synthesis of 11, which is outlined in Scheme 1. Starting from 5-
chloro-2-methyl-thiophene (4) standard Friedel–Cras condi-
tions yielded ketone 5 and glyoxylate ester 8. The ester 6 was
obtained via an oxidative rearrangement from ketone 5. Suzuki
coupling yielded the functionalized esters 7 and 9. Compound
10 was prepared by aminolysis of glyoxylate ester 9, which was
subsequently used in a Perkin condensation with ester 7 to
obtainmaleimide 11. Scheme 1 summarizes the synthesis of the
symmetric diarylmaleimide 11.Fig. 2 Structures of diarylmaleimides 2 and 3.
This journal is © The Royal Society of Chemistry 2014Photochromic properties
The photoisomerization of photochromic compounds in polar
solvents is essential for applications in biological assays. As
dimethyl sulfoxide is a standard solvent for inhibitor screening,
this solvent was used to investigate the switching ability of the
diarylmaleimides. The ring closure is suppressed in polar
solvents due to a twisted intramolecular electron transfer. This
phenomenon is well-investigated for maleimides bearing two
benzothiophenes.12 To enhance the switching ability of DTEs
the introduction of sterical hindrance either by bulky substit-
uents on the aryl moieties or on the bridge is a widely applied
concept.26–28 As seen from the perspective of the pharmacophore
only the introduction of sterically demanding substituents on
the aryl moieties are possible. Otherwise the ability to form
relevant hydrogen bonds between the maleimide and the
backbone of the enzyme is lost. We decided to replace the
benzothiophene moieties by phenyl substituted thiophenes.
Despite this change the structure of the chromophore is still
similar to the pharmacophore, but the photochromic properties
improve signicant. The exchange of the methyl-benzothio-
phenes in 2 by one or twomethyl-phenyl substituted thiophenes
in 3 or 11, resp., stabilizes the antiparallel conformation, which
favors the photochemical ring closure reaction.Chem. Sci., 2014, 5, 4794–4799 | 4795
Fig. 3 Photochromic properties of compound 11 (10 mm in DMSO):
absorption spectra changes upon continuous irradiation for 0, 2, 6, 12,
18, 40 and 60 s with light of lmax ¼ 312 nm.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
A
ug
us
t 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
0/
04
/2
01
5 
10
:0
1:
48
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineThe photoisomerization was monitored by absorption spec-
troscopy (Fig. 3) and the photostationary states (PSS) were
determined by HPLC measurements (see ESI†).
Upon irradiating (l ¼ 312 nm) the dissolved compounds 2, 3
and 11, a rapid color change was observed, resulting in new
absorption bands characteristic for each compound. The
photochromic properties are summarized in Table 1. Replacing
the benzothiophene moieties by phenyl-substituted thiophenes
has two consequences: (1) the absorbance maxima for the
closed isomers shi bathochromically from compound 2 to
compound 11. Therefore light of longer wavelength is suﬃcient
for the isomerization. (2) The photoconversion becomes more
eﬃcient as indicated by PSS increasing from 62% to 94%. Such
high PSS is advantageous for binding investigations as the
interaction with the enzyme can be restricted to mainly one
photoisomer.
By way of example, Fig. 3 illustrates the photoisomerization
of compound 11. Upon irradiating (l ¼ 312 nm) of compound
11 in dimethyl sulfoxide solution, a rapid color change from
light green to deep purple was observed, resulting in new
absorption bands at 390 nm and 580 nm (marked with black
arrows in Fig. 3). The isosbestic points (Table 1) indicate a clean
two-component switching. Repetition of the photo-
isomerization of compound 11 shows a good fatigue resistance
over ve cycles (see ESI†).Table 1 Photochromic properties of diarylmaleimides 2, 3 and 11 (10
mm in DMSO)
Entry Compound
lmax open
[nm]
lmax closed
[nm]
Isosbestic
points [nm] PSSa
1 2 278 353, 495 293 62%
2 3 274 329, 527 291 87%
3 11 290 390, 580 316, 410, 430 94%
a Determined by HPLC measurements.
4796 | Chem. Sci., 2014, 5, 4794–4799Enzyme inhibition
Next, the inhibitory eﬀect of the photoresponsive compounds 2,
3 and 11 against sirtuins in a homogenous uorescent assay,
previously established by Jung et al. was determined. The
enzymatic conversion was quantied using (S)-[5-acetylamino-
1-(4-methyl-2-oxo-2H-chromen-7-ylcarbamoyl)-pentyl]-carbamic
acid benzyl ester also termed ZMAL29 as uorescent substrate
for deacetylation followed by a tryptic digestion step.30 1 (Ro31-
8220) has an IC50 value of 0.8 mm and is the most potent BIM
inhibitor reported so far for human Sirt2 (hSirt2).14,16 In
comparison to 1 the photoresponsive diarylmaleimides 3 and
11 showed similar inhibition strength against hSirt2. The
respective IC50 values are given in Table 2.
The scaﬀold of compound 2 is structurally closest related to
1. Its open isomer exhibits a lower IC50 value against hSirt2
(Table 2, entry 6) than its closed photoisomer. By the exchange
of one of the benzothiophenes in 2 by a phenyl substituted
thiophene as in compound 3 the inhibition activity increases.
However, the open and the closed photoisomer of compound 3
show the same inhibition (Table 2, entries 4 and 5). The
replacement of the second benzothiophene from themaleimide
moiety by a phenyl substituted thiophene in compound 11
yields an inhibition corresponding to an IC50 value of 4.2 mm of
the open photoisomer. The ring closed photoisomer of 11
shows a twentyfold lower enzyme inhibition with 92.3 mm
(Table 2, entries 2 and 3). Diarylmaleimide 11 gives the most
signicant change in hSirt2 inhibition activity for both photo-
isomers and therefore its isotype selectivity against human Sirt1
(hSirt1) and human Sirt3 (hSirt3) under the same assay condi-
tions30 as used for hSirt2 were determined. The isotype selec-
tivity for BIM 1 (Ro31-8220) is only small (Table 2, entry 1).
Therefore inhibitor concentrations at 20 mm and 200 mm were
used to determine the enzyme activity using nicotinamide as a
reference. Neither the open isomer nor the closed isomer of 11
inhibited hSirt1 or hSirt3 signicantly (Table 2, entries 2 and 3).
Next, the enzyme activity of hSirt2 was controlled by light
under assay conditions. Therefore, the photochemical conver-
sion from the closed isomer to the open isomer of 11 and the
corresponding inhibitory activity were measured as a function
of time (Fig. 4). Hence the less potent closed isomer of 11 was
incubated with the enzyme under assay conditions and irradi-
ated over a period of 30 min with a green LED (2.5 W, 530 nm
emission maximum). Then the cofactor NAD+ and ZMAL were
added and the assay was performed under the usual conditions.
Fig. 4 illustrates the time course of the isomerization (dotted
line) and inhibitory activity (straight line) of 11. The irradiated
samples switched from the less potent closed form of 11 to the
signicantly more potent open form.
Aer 20 min complete photochemical conversion of 11 and a
constant inhibition value are observed. The determined values
correspond to the inhibition activity of the open isomer of 11
(Table 2) proving that the photoisomerization is possible in the
presence of the enzyme under assay conditions.
Additionally, the open photoisomer of 11 was tested for
cellular activity using hyperacetylation of tubulin31 as a marker.
11 showed tubulin hyperacetylation and hence targetThis journal is © The Royal Society of Chemistry 2014
Table 2 IC50 values of the photochromic diarylmaleimides 2, 3 and 11 and 1 (Ro31-8220) as BIM reference
Entry Compound hSirt1 IC50 [mM] hSirt2 IC50 [mM] hSirt3 IC50 [mM] hSirt2 IC50 closed/IC50 open
1 1 (ref. 14 and 15) 3.5  0.4 0.8  0.2 3.7  0.2
2 11 open n.i.a 4.2  0.8 n.i. 22
3 11 closed n.i. 92.3  8.0 n.i.
4 3 open —b 2.3  0.4 — 1
5 3 closed — 2.1  0.3 —
6 2 open — 12.9  5.4 — 2
7 2 closed — 23.1  5.6 —
a n.i.: no inhibition [<10% @ 20 mm]. b —: not tested.
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View Article Onlineengagement similar to the control inhibitor 1 (Ro31-8220)14 (see
ESI†). But further studies are required as we cannot rule out
indirect eﬀects as the compounds have not been optimized for
selectivity, e.g. against kinases.
Molecular docking
In order to rationalize the observed in vitro activities docking of
the open and closed form of the diarylmaleimides to hSirt2
(PDB-ID 3ZGO) was carried out. Docking of the open form of the
isomers 2, 3 and 11 to hSirt2 resulted in a similar interaction at
the acetyl-lysine channel of hSirt2 (see ESI†) favoured by a
hydrogen bond with the backbone of Val233 and van-der-Waals
interactions with hydrophobic and aromatic residues (Phe96,
Phe119, Ile169, His187, Phe234, and Phe235). Val233 represents
a conserved amino acid in sirtuins that binds the amide group
of the acetyl-lysine substrate. The open photoisomers t nicely
to the acetyl-lysine pocket of hSirt2. The angle between the
aromatic rings and the maleimide is for all open photoisomers
around 50 deg., which allows the accommodation of both
aromatic substituents in the acetyl-lysine pocket. The closed
photoisomer of 11might be too big (distance from both ends of
the phenyl ring 14.7 A˚ compared to 12.9 A˚ for 3 and 10.9 A˚ for 2)
and rigid to interact in a similar way within the binding pocket
as the open and exible isomer of 11 (Fig. 5). The dockingFig. 4 Time course of the photochemical conversion from the closed
to the open form of 11 (dotted line) and the corresponding inhibitory
activity against hSirt2 (straight line) upon continuous irradiation with
light of lmax ¼ 530 nm for 0, 2.5, 5, 7.5, 10, 20 and 30 min at an assay
concentration of 10 mM.
This journal is © The Royal Society of Chemistry 2014results suggest that the terminal aromatic rings and methyl
groups clash with His187 and Phe235 resulting in a diﬀerent
orientation at the binding pocket compared to the closed
isomers of 2 and 3 (Fig. 6). As a consequence, the distance
between the maleimide and Val233 backbone carbonyl group is
increased (3.85 A˚) disabling the hydrogen bond formation (see
ESI†). Only the closed photoisomers of 2 and 3 t well to the
binding pocket and make favourable van-der-Waals interac-
tions with the aromatic and hydrophobic residues (see ESI†).
Docking to the apo Sirt3 (PDB-ID 3GLS) substrate binding
pocket was not possible due to a diﬀerent conformation of the
exible loop anking the acetyl-lysine channel. Especially, the
residues Phe157, Arg158 and Phe294 block part of the substrate
binding pocket observed in hSirt2 (see ESI†). Thus, the docking
suggests that the observed selectivity of the photochromic
inhibitor 11 arises from a diﬀerent orientation of amino acid
residues located at the entrance of the acetyl-lysine channel of
hSirt3.
In case of apo hSirt1 (PDB-ID 4IG9), which shows also an
open conformation of the substrate binding site, the docking of
the photoisomers of 11 resulted in less favourable complexes.Fig. 5 Comparison of the binding mode of photoisomer 11 at hSirt2 in
the open (brown) and the closed form (dark green). The two residues
(Phe235 and His187) that hinder the proper orientation of the closed
photoisomer 11 are colored cyan. Water molecules are shown as red
spheres. The hydrogen bond to the backbone of Val233 is shown as
black line (distance between the NH group of closed 11 and the
backbone carbonyl of Val233 is 3.19 A˚).
Chem. Sci., 2014, 5, 4794–4799 | 4797
Fig. 6 Comparison of the binding mode of closed photoisomer 3
(orange) and closed photoisomer 11 (dark green) at hSirt2. Water
molecules are shown as red spheres.
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View Article OnlineDue to the orientation of Phe414 the pocket shows a diﬀerent
shape compared to hSirt2 which hinders the formation of a
hydrogen bond between Val233 and the maleimide group of the
docked inhibitors (see ESI†). Compound 11 is therefore isotype
selective for hSirt2 and although 11 shows no higher potency
than 1, it is the rst example for a potent photochromic mal-
eimide sirtuin inhibitor with such selectivity and the rst
example for a photochromic inhibitor combining elements of a
chromophore and a pharmacophore within one structure.Conclusions
In summary, we have merged structural elements of the well
investigated photochromic diarylmaleimides with biological
relevant bisindoylmaleimides, which are known for their sirtuin
inhibitory activity, yielding potent and isotype selective photo-
chromic inhibitors. The new compounds are the rst photo-
chromic epigenetic inhibitors described so far. The
photochromic and enzyme inhibition properties of the new
diarylmaleimides were optimized by variation of the maleimide
scaﬀold. Exchange of the benzothiophene moieties by phenyl
substituted thiophenes led to nearly quantitative photosta-
tionary states of the diarylmaleimides in dimethyl sulfoxide and
subtype selective inhibition of hSirt2 in the low micromolar
range. The photoisomers of diarylmaleimide 11 diﬀer more
than 20-fold in their inhibition ability. Irradiation of the closed
photoisomer of 11 in the presence of the enzyme isomerizes the
compound into the more potent open photoisomer allowing the
remote control of the enzyme activity by green light. The
inhibitory activity of the open photoisomer of 11 was also tested
in cell culture. 11 induced hyperacetylation of tubulin, but
further studies are necessary to eliminate indirect eﬀects.
The new diarylmaleimides combine in their molecular
structure photochromic and selective enzyme inhibiting prop-
erties. They are valuable tools for the investigation of molecular
binding mechanisms of sirtuins and the application of the
concept to other privileged structures of the bisindoylmalei-
mide family may be readily envisaged.4798 | Chem. Sci., 2014, 5, 4794–4799Acknowledgements
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